Replies to post #969 on Dendreon Corp fka DNDNQ

[DewDiligence]

>There is a different in looking at independent endpoints or independent interim looks for stopping and looking at endpoints that are surrogates of one another. In the former cases, yes allocating p value properly is a must. In the latter case, it is not necessary. I posted the below follow-up to Clarksterh's post on iVillage…<

That’s non-responsive to the point I raised in #960 concerning FDA policy about “free” or implicit p-value for survival, which has nothing to do with interim data looks.

Clearly, free p-value is not the FDA’s standard M.O. else companies would not design in explicit p-value allocations for survival.